10/08/2022
EyRIS is proud to announce a watershed collaboration with Remidio that will transfigure the delivery of diabetic retinopathy screening for the rising number of patients with diabetes.
The partnership envisions making DR screening more mobile, accessible, and cost-effective, for astute healthcare professionals. The collaborative solution is expected to lower the barrier of entry for caregivers who have always wanted to provide this critical service to an ever-increasing population of patients with diabetes across the globe.
Studies conducted have shown that EyRIS’ SELENA+, jointly developed by Singapore Eye Research Institute (SERI) and National University of Singapore School of Computing, can achieve a sensitivity of 100% to detect vision-threatening diabetic retinopathy* using fundus images captured by Remidio FOP (Fundus on Phone) handheld fundus camera.
Today, diabetes has affected more than 530 million people, and it is predicted that by 2045, it will affect 780 million people globally. All patients with diabetes are advised to have their eyes screened at least once a year to prevent blindness from DR. This mammoth task of being able to screen every patient of diabetes can only be achieved using such technology offered by Remidio and EyRIS.
Stay tuned to this space for more details on the impact of this partnership.
*Vision-threatening Diabetic Retinopathy is defined as a fundus image displaying lesions that is consistent with “severe diabetic retinopathy or higher grade”, using the ICDRS Scale.
https://www.linkedin.com/posts/steven-ang-85b60218a_eyescreening-eyecare-eyehealth-activity-6962944364511719424-LjDV?utm_source=linkedin_share&utm_medium=member_desktop_web
